Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2022-A00730-43 | Other Identifier | ID-RCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| URC-CIC Paris Descartes Necker Cochin | OTHER |
Not provided
Not provided
Not provided
Not provided
The treatment of a local distal gastric cancer remains surgical before or after chemotherapy. Partial gastrectomy is recommended for distal location cancer The recommendations for restoring continuity are less evident. There are two main techniques: the Roux-En-Y (REY) requiring 2 anastomoses (gastro-jejunostomy and entero-enterostomy) and the Billroth 2 (B2) with a single anastomosis (gastro-jejunostomy). The choice remains matter of debate.
There was no difference on the global health status score from the QLQ-C30 questionnaire. However, the health-related quality of life (HRQoL) was significantly improved only in the REY group between pre- and post-gastrectomy. A significant difference for endoscopic gastritis in favor of the REY group was reported.
The purpose of this study is to determine which surgical technique improve the health related quality of life after distal gastrectomy.
The realization of REY suggests an improvement of the HRQoL after distal gastric resection in comparison to the B2 anastomosis justifying the need of a RCT on the topic. Moreover, the REY could improve the gastro-intestinal symptoms and gastritis. The investigators hypothesize that the REY intervention after distal gastrectomy will improve HRQoL for 3 targeted dimensions of the EORTC QLQ-OG25 questionnaire (eating, reflux, pain and discomfort) in patients with gastric cancer.
All patients with a distal gastric cancer treated in curative intent by surgery with distal gastrectomy should be included. The choice of this population belongs in the fact that no reconstruction according billroth2 are performed for other gastric cancer requiring a total gastrectomy. Therefore, all patients treated by total gastrectomy need to be excluded. Secondly, the increase in survival of this population in the past decade araising to 75% at 5 years allows investigators to question the quality of life after surgery.
The anastomosis is realized with the proximal jejunum without entero-enterostomy in the first 70 cm after the angle of Treitz. The gastrojejunostomy could be ante-colic or trans-mesocolic. The anastomosis could be performed according the surgeon decision (mechanical or handsewn, isoperistaltic or anisoperistaltic).
The length of jejunum of the Y section needs to be at least 60 cm. The Roux-en-Y anastomosis could be antecolic or transmesocolic. The anastomosis could be realized according the surgeon decision (mechanical or handsewn, isoperistaltic or anisoperistaltic).
The choice between these two techniques will not add an increased risk to the patient since they are both recommended by national guidelines, they are both performed as standard care and there is no difference in Quality of Life at long term.
During surgery:
Interventions added for the research are:
Expected benefits for the participants: Improve HRQoL after distal gastrectomy. Patients will not be exposed to a specific risk as the two methods of reconstruction are described and used in the routine.
The design of the study (without excessive invasive exam) and the routine care monitoring associated to a better HRQoL evaluation compared to the "classic" post-operative follow-up of patient will help patient decision to participate to the study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Billroth 2 (B2) | Experimental |
| |
| Roux-En-Y (REY) | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Billroth 2 (B2) | Procedure | B2 technique requires a single anastomosis (gastro-jejunostomy) after distal gastrectomy |
|
| Measure | Description | Time Frame |
|---|---|---|
| HRQol with 3 targeted dimensions | European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, OesophagoGastric 25 (EORTC QLQ-OG25) at 1 year post surgery with 3 targeted dimensions : eating, reflux, pain and discomfort. Health-related Quality of life (HRQoL) will be considered as being improved in one arm if at least one of the 3 targeted dimensions is significantly improved without a significantly deterioration for the other 2 targeted dimensions :
| One year post-surgery |
| Measure | Description | Time Frame |
|---|---|---|
| Other EORTC QLQ-OG25 dimensions | Other dimensions of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, OesophagoGastric 25 (EORTC QLQ-OG25) questionnaire :
| Baseline, 3 months, 6 months, 1 year and 2 years post-surgery |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Alexandre CHALLINE, MD, PhD | Contact | +33 1 49 28 25 33 | alexandre.challine@aphp.fr | |
| Christelle AUGER | Contact | +33 1 58 41 11 86 | christelle.auger@aphp.fr |
| Name | Affiliation | Role |
|---|---|---|
| Alexandre CHALLINE, MD, PhD | Assistance Publique - Hôpitaux de Paris | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital Saint-Antoine | Recruiting | Paris | 75012 | France |
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
| D013274 | Stomach Neoplasms |
| ID | Term |
|---|---|
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D004066 | Digestive System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000713 | Anastomosis, Roux-en-Y |
| ID | Term |
|---|---|
| D000714 | Anastomosis, Surgical |
| D013514 | Surgical Procedures, Operative |
| D013505 | Digestive System Surgical Procedures |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Roux-En-Y (REY) | Procedure | REY technique requires 2 anastomoses (gastro-jejunostomy and entero-enterostomy) after distal gastrectomy |
|
| Other HRQoL dimensions | Other dimensions of the HRQoL measured with the EORTC QLQ-C30 ( European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaires, Core 30) questionnaire will be described at baseline, 3 months, 6 months, 1 year and 2 years post-surgery :
| Baseline, 3 months, 6 months, 1 year and 2 years post-surgery |
| Longitudinal changes of each HRQoL dimension | - The long-term HRQoL after surgery for gastric cancer at 2 years | The long-term HRQoL (EORTC QLQ-OG25 questionnaire) after surgery for gastric cancer at 2 years |
| Longitudinal changes of each HRQoL dimension | The long-Term HRQoL after surgery for gastric cancer at 2 years | et The long-term HRQoL (EORTC QLQ-C30 questionnaire) after surgery for gastric cancer at 2 years |
| The long-term HRQoL after surgery for gastric cancer at 2 years | The long-term HRQoL after surgery for gastric cancer at 2 years (EORTC QLQ-C30 ) | 2 years post-surgery |
| The long-term HRQoL after surgery for gastric cancer at 2 years | The long-term HRQoL after surgery for gastric cancer at 2 years (EORTC QLQ-OG25) | 2 years post-surgery |
| The post-operative morbidity rates at 90 days | The postoperative morbidity at 90 days will be measured with the several following complications: Surgical site infection / leakage, gastroparesis, gastro-intestinal occlusion, stasis syndrome, dumping syndrome, ulcerative pathology | 90 days post-surgery |
| The post-operative morbidity rates at 1 year | The postoperative morbidity at 1 year post surgery will be measured with the several following complications: Surgical site infection / leakage, gastroparesis, gastro-intestinal occlusion, stasis syndrome, dumping syndrome, ulcerative pathology | 1 year post-surgery |
| The endoscopic biliary reflux rate and gastritis at 1 year post surgery | The biliary reflux and gastritis will be assessed by endoscopy at 1 year post-surgery | 1 year post-surgery |
| The rate of proton pump inhibitor (PPI) use at 3 months, 6 months, 1 year and 2 years post-surgery | The use of PPI will be measured by taking PPI in the past week at 3 months, 6 months, 1 year and 2 years post-surgery | 3 months, 6 months, 1 year and 2 years post-surgery |
| The survival at 1 year | The survival at 1 year post-surgery will be recorded by OS and DFS rate. DFS, defined as the time from surgery and locoregional recurrence, occurrence of distant metastases or second gastric cancer, or death (all causes) or the date of the last follow-up, at which point data will be censored. OS, defined as the time from surgery to the death from any cause or the date of the last follow-up, at which point data will be censored. | 1 year post-surgery |
| The survival at 2 years | The survival at 2 years post-surgery will be recorded by OS and DFS rate. DFS, defined as the time from surgery and locoregional recurrence, occurrence of distant metastases or second gastric cancer, or death (all causes) or the date of the last follow-up, at which point data will be censored. OS, defined as the time from surgery to the death from any cause or the date of the last follow-up, at which point data will be censored. | 2 years post-surgery |
| D005767 | Gastrointestinal Diseases |
| D013272 | Stomach Diseases |